The aim of this article is to study the indices of cellular, humoral immunity and nonspecific resistance, indices of free radical lipid oxidation and thrombocytoactive properties of periodontal tissues in animals with adjuvant periodontitis. In our study, adjuvant periodontitis was reproduced by the method of A.M. Kaminsky, immunizing rats with a homologous periodontal tissue in admixture with a Freund's adjuvant in a 1: 1 ratio. The course consisted of four single injections of 0.2 ml per animal intramuscularly at weekly intervals. Immunization did not lead to changes in the development and behavior of rats. One month after immunization, experimental animals experienced symptoms characteristic of generalized periodontitis in humans. They were manifested in the form of gums, resorption of alveolar bone, mobility and tooth loss. The induction of adjuvant periodontitis in experimental animals led to a significant increase in lipid peroxidation processes in periodontal tissues and a decrease in SOD and catalase activity. In animals with adjuvant periodontitis, which have been injected with periodontal polypeptides, there is a decrease in the reactions of GF compared with patients. In particular, there was a 40.9% decrease in the level of TBK-active products, although the level of MDA accumulation in the incubation process had not decreased significantly. It is noteworthy that in this group of animals increased activity of AO enzymes, which in patients was sharply reduced. Significant changes in the BPO lipid state were also observed in the blood of animals. The peroxidation reactions were significantly reduced, but not as significantly as in periodontal tissues. In particular, spontaneous erythrocyte hemolysis was lower by 14.2%, the level of TBK-active products by 39.4%, and MDA by 34.9%. An increase in the activity of SOD and catalase was observed, as well as a 40.4% decrease in the concentration of ceruloplasmin, which testifies to the elimination of the inflammatory response upon introduction of polypeptides. The treatment of animals with periodontylline was accompanied by an increase in the anti-aggregation properties of periodontal tissues. This is confirmed by the following indicators of the aggregate: the angle of aggregation is reduced by 31.8%, the optical density by 29%, the aggregation time is increased by 42.9% compared with the group of animals with adjuvant periodontitis. The introduction of parodontilin had a pronounced effect on the condition of blood clotting and fibrinolysis. We observed a significant increase in recalcification time, thrombin, prothrombin time. If the disease has a significant increase in the time of euglobulin fibrinolysis, then in the treatment of this indicator becomes less by 69.4%, the products of para-coagulation disappear from the bloodstream and the concentration of fibrin degradation products decreases. The treatment of animals was accompanied by an increase in immunity, which was manifested by an increase in T and B lymphocytes and Ig G. titer. Studies have shown that the treatment of diseased animals with a polypeptide drug leads to an improvement in the cellular, humoral immunity and nonspecific resistance of the organism, as well as the presence of a pronounced immunomodulatory effect of periodontin. The previously established relationship between blood clotting systems, sex, immunity, nonspecific resistance of the organism is confirmed in these experimental studies. If the induction of periodontitis is primarily associated with autoimmune processes, leading to impaired homeostasis, then the introduction of periodontin has a modulating effect on both immunity and indicators of lipid peroxidation and microcirculatory and coagulative hemostasis . In animals, regression of dental symptoms was noted, signs of periodontal inflammation, bleeding, swelling disappeared, and tooth mobility decreased. These data indicate the high therapeutic efficacy of thymic drugs in the treatment of generalized periodontitis. Research in this area remains relevant.
Disorders in the periodontal tissues in generalized periodontitis have a significant negative impact on the patient’s somatic and psycho-emotional health, causing not only dental, but also medical and social difficulties. Although scientific research has been studied, the search for new drugs for treatment and prevention of periodontal tissue diseases, the introduction of new methods have been provided, but the prevalence of generalized periodontitis includes 88-100% among adults. Destructive periodontal changes in chronic generalized periodontitis (CGP) are often irreversible and, in combination with dysfunction of the dento-alveolar apparatus and premature loss of teeth, they impair the quality of patients’ life and decrease their social adaptation. SIgA is the most important external secretory immunoglobulin. The functions of sIgA are the following: agglutination of bacteria, change of bacterial metabolism, delayed colonization of microorganisms, neutralization of viruses, bacterial toxins, enzymes, decrease the virulence of infectious agents and increase the opsonization of microorganisms. Receptors of slgA molecules have an affinity for some proteins of pathogens and, therefore, provide the formation of passive immunity against bacterial and viral infections. The aim of the work was to evaluate the clinical efficacy of the proposed immunomodulatory treatment for patients with severe generalized periodontitis. To achieve this goal, a clinical case of the drug Derinat as an addition to the complex therapeutic treatment of severe generalized periodontitis in a patient with a deficiency of secretory immunoglobulin A in the oral fluid (54, 6 mg/l) was used and presented by us. The patient’s treatment was done comprehensively, purposefully, individually including local and general therapy, and effective, conservative, surgical and orthopedic measures in the conditions of outpatient supervision of patients were also performed. The periodontal protocol included following steps: 1) a comprehensive examination of general and dental status; 2) professional oral hygiene, elimination of aggravating factors, selective grinding of teeth; selection of individual care products; 3) the appointment of the antibacterial drug such as Azithromycin 500 mg - 7 days; 4) immunomodulatory therapy with the use of Derinat by applications in periodontal pockets for 15 minutes - 7 days; 5) prosthetics with partial removable plate prostheses on the upper and lower jaws; 6) evaluation of intermediate results of treatment: repeated clinical examination and completion of a control periodontal card. The data, which has been obtained, indicated a significant positive trend in treatment, the absence of complaints on 2nd day of treatment and clinical improvement on 3rd or 4th days. Dental status data (hygiene index (1,0), PMA index (0%), periodontal index (1,2), bleeding index (1) and depth of periodontal pockets (2-3 mm)) has been significantly improved after the proposed treatment. The extension of the remission period is more than a year. Conclusions. The use of immunomodulatory drugs in the complex therapy of patients with chronic generalized periodontitis can significantly improve the results of conservative treatment, reduce the treatment time and prolong the period of remission due to the pathogenetic effect on the key links of the immune defense in the oral cavity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.